We are actively looking for partners who wish to enter the Chinese market with their new drugs, devices and digital health assets that are in late-stage development or are recently approved and commercialized in regulated markets. in addition, we are seeking generic products that could provide significant market opportunities in China. We will consider in-licensing, acquisition, co-promotion, revenue-sharing, and other partnering opportunities.
Established in 1995 in Long Island, New York and 2003 in Zhongshan, China, A&Z Pharmaceutical is a fully integrated pharmaceutical company, present across the entire pharmaceutical value chain from Research and Development, Finished Formulations to Marketing and Distribution in the US and China.
Established in 2004, focusing on the promotion of CNS products, Ranxin is one of the most successful distribution sales, and marketing companies in China. The company has established partnerships with major global pharmaceutical companies for drug distribution in China.
Our investors value partnership and diversity of minds to advance the science of medicine. By working together, we plan to accelerate the development of transformative CNS treatments that will improve the lives of peoplein China and everywhere.
